Free treatment and clinical trial access.
Did you realize the National Cancer Institute offers free consultation, treatment and travel for fibrolamellar (FLC) patients? Dr. Tim Greten, MD spearheads the NCI’s fibrolamellar efforts and is available to speak with anyone in our community interested in learning more. Besides offering tailored treatment for each patient per consultation, there are also two clinical trials […]
October 1 was Rare Cancer Day
Tuesday October 1, 2019 was Rare Cancer Day. This year is especially important because at the Fibrolamellar Cancer Foundation (FCF) we are celebrating 10 years of bringing awareness to this disease. We are proud to have contributed nearly 8 million dollars to researching cures and treatments for this horrific disease. Despite the fact that […]
Important U of Washington study published
FLC tumors contain a unique genetic defect that fuses together portions of genes called DNAJ and PKAc. DNAJ helps fold other proteins into their correct shapes, whereas PKAc is an enzyme involved in cell communication. An FCF supported research team at the University of Washington, Seattle now report that the DNAJ-PKAc fusion additionally recruits […]
St. Jude Children’s Research Hospital and University of Tennessee co-host major fibrolamellar research collaboration summit focused on immunotherapy
The summit brought together some of the most innovative researchers, clinicians and funders serving the FLC community, including Johns Hopkins, Rush University, University of Maryland, along with co-hosts St. Jude Children’s Research Hospital and U of Tennessee and The Fibrolamellar Cancer Foundation. The meeting highlighted many of the latest discoveries in FLC immunotherapy which were […]
Collaborative research seeking therapeutic treatment
Cornell publishes fibrolamellar discovery which could serve as part of a new therapeutic approach. This study is a great example of the multi-institution collaboration strategy FCF continues to fund in our quest for curative therapies. Small molecules inside our bodies called “microRNAs” have emerged as very important players in the development of a wide variety […]
2019 FCF Scientific Conference
SAVE THE DATE: November 5-7, 2019 in Greenwich, CT. Details to follow.
Report on 2017 Scientific Conference
The distinquished Journal of Hepatocellular Carcinoma has published a report on FCF’s 2017 Scientific Conference. Authors are Drs. Ted Kastenhuber, Ghassan AbouAlfa, and John Craig who coordinated the writing and editing. FCF thanks these doctors for their time and commitment to this article. The article, which can be viewed here, is titled, “Road map for […]
Duke University Research Conversation and Facilities Tour
Dr. Anna Mae Diehl, Professor, Department of Medicine at Duke University and by Dr. Cynthia Guy, Associate Professor, Department of Pathology at Duke University Medical Center hosted an FCF event in October 2018. The event showcased the important fibrolamellar research work being conducted at this prestigious institution. It included an overview of FCF’s research mission, […]
FCF Scientific Director
Mark Furth, PhD, has joined FCF as Scientific Director. Having a full time scientific director adds a new realm of professionalism. Dr. Furth was educated at Harvard and University of Wisconsin. His research credentials include working at National Institute of Health, Memorial Sloan Kettering, Cold Spring Harbor Laboratories, Glaxo Smith Kline and Wake Forest University.
Social Security Agency Expands Compassionate Allowance List
Nancy A. Berryhill, Acting Commissioner of Social Security, announced five new Compassionate Allowance conditions: Fibrolamellar Cancer, Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS), Megalencephaly Capillary Malformation Syndrome (MCAP), Superficial Siderosis of the Central Nervous System, and Tetrasomy 18p. Compassionate Allowances is a program to quickly identify medical conditions and serious diseases that meet Social Security’s standards for […]